16:09 , Apr 26, 2018 |  BC Innovations  |  Emerging Company Profile

Mammoth makes Dx CRISPR

Mammoth Biosciences emerged from stealth with an exclusive license to Jennifer Doudna’s CRISPR-based diagnostics technology, which could enable faster diagnosis of a range of diseases than PCR-based sequencing and culture-based techniques and be more adaptable...
22:36 , Apr 4, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: March 2018

New Therapeutic Targets and Biomarkers: March 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during March 2018. Therapeutic targets are defined as any protein, gene or other...
18:13 , Apr 3, 2018 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Gene therapy Nuclear-targeted, catalytically inactive Ruminococcus flavefaciens Cas13d could be used for therapeutic targeting of single-stranded RNAs and RNA splicing in cell nuclei. The fusion consists of Cas13d from the XPD3002 strain of R....
23:36 , Mar 29, 2018 |  BC Innovations  |  Tools & Techniques

Cutting-edge diagnostics

Following the splash that CRISPR has made in the world of therapeutics, academics are expanding the tool kit of Cas enzymes and finding new uses in diagnostics. Early hints suggest the technology could become competitive,...
23:49 , Mar 16, 2018 |  BC Extra  |  Preclinical News

New Cas enzyme can edit RNA, target tau

In Cell , researchers from the Salk Institute for Biological Studies discovered a new RNA-targeting CRISPR enzyme, CRISPR-associated protein 13d (Cas13d), and showed it could be used to edit the transcript of a frontotemporal dementia...
16:03 , Mar 15, 2018 |  BC Extra  |  Company News

Arbor launches with $15.6 million, new CRISPR enzyme

Arbor Biotechnologies Inc. (Cambridge, Mass.) emerged from stealth mode on Thursday with a study detailing the discovery of a new CRISPR enzyme, CRISPR-associated protein 13d (Cas13d), and a $15.6 million series A round that closed...